LEADER 01720oam  2200445Ia 450 
001 9910698842903321
005 20090521121400.0
035   $a(CKB)5470000002397437
035   $a(OCoLC)326879738
035   $a(EXLCZ)995470000002397437
100   $a20090519d2005      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $enucleic acid testing (NAT) for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV), testing, product disposition, and donor deferral and reentry
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,$d[2005]
215   $aii, 41 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on May 19, 2009).
300   $a"Draft guidance".
300   $a"July 2005".
320   $aIncludes bibliographical references (pages 24-25).
517   $aGuidance for industry 
606   $aNucleic acids$zUnited States$xTesting
606   $aHIV (Viruses)$xDiagnosis$zUnited States
606   $aHepatitis C virus$xDiagnosis$zUnited States
606   $aBlood donors$xGovernment policy$zUnited States
615  0$aNucleic acids$xTesting.
615  0$aHIV (Viruses)$xDiagnosis
615  0$aHepatitis C virus$xDiagnosis
615  0$aBlood donors$xGovernment policy
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910698842903321
996   $aGuidance for industry$93434577
997   $aUNINA